However, earlier drug discovery attempts involving FDA-approved drug screens have resulted in the identification of leukemia-subtype specific inhibitors against for example AML1-ETO-positive acute myeloid leukemia (AML) and NOTCH1-mutated T-cell ALL [25,26]. Here, RUNX1 is linked to acute myeloid leukemia.